AUG 18, 2026 · JOURNAL ARTICLE
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer: Real-World Outcomes and Treatment Transition Patterns in a Chinese Cohort
Current Oncology
Real-world retrospective cohort study demonstrating clinically meaningful efficacy and safety of T-DXd in heavily pretreated HER2-positive metastatic breast cancer, but limited by single-center design, lack of comparator arm, and acknowledged biases in maintenance analysis.
Reported
Sample size173
Median follow-up14.3 months
Median progression-free survival14.1 months